

Davidson, Mark

From: Rizwana Sproule <RSproule@KitePharma.com>
Sent: Wednesday, August 02, 2017 4:41 PM
To: Davidson, Mark
Cc: Nadia Agopyan; Alex Babayan
Subject: RE: Kite Pharma 125643 Clinical Pharmacology IR August 2, 2017

Hi Mark

I confirm receipt of the email request below.

*Regards
Rizwana*

From: Davidson, Mark [<mailto:Mark.Davidson@fda.hhs.gov>]
Sent: Wednesday, August 2, 2017 1:39 PM
To: Rizwana Sproule <RSproule@KitePharma.com>
Cc: Nadia Agopyan <NAgopyan@KitePharma.com>; Alex Babayan <ABabayan@KitePharma.com>
Subject: Kite Pharma 125643 Clinical Pharmacology IR August 2, 2017
Importance: High

Dear Dr. Sproule

If possible, please evaluate impact of tumor burden on KTE-C19 PK profiles (Cmax, AUC0-28, and Tmax).

Please respond by COB 08/09/2017.

Thank You

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."

This e-mail contains information that may be confidential. If you are not the intended recipient, please delete the e-mail and notify the sender at Kite Pharma immediately.